Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions Patents (Class 424/1.11)
  • Patent number: 10736976
    Abstract: Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: August 11, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston
  • Patent number: 10730952
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 10718778
    Abstract: The present invention relates to methods for detecting sulfenylation within thiol groups in proteins, metabolites, or materials. Protein sulfenylation (Cys-SOH) describes the reversible post-translational modification of protein thiols by hydrogen peroxide, and plays a central role in oxidative signaling (see, e.g., Paulsen, C. E. & Carroll, K. S. 2013 Chemical Reviews 113, 4633-679). Growth factor stimulation activates NADPH oxidase enzymes, releasing a local burst of hydrogen peroxide, which transiently oxidizes the nuclcophilic cysteine of protein phosphatases and other proximal redox active thiols (see, e.g., Paulsen, C. E. et al., 2012 Nature Chemical Biology 8, 57-64). In addition to masking functional cysteine's, sulfenylation is also a critical intermediate towards irreversible cysteine oxidation.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Brent R. Martin, Christopher Baker Tom
  • Patent number: 10702478
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g. as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 7, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
  • Patent number: 10695450
    Abstract: The present invention relates to a method for the synthesis of a radioactive agent composition comprising at least a purification step carried out in the presence of an antioxidant, to the composition obtained by this method comprising radioactive agent and excipient, and to the method for preventing radiolysis of radioactive agent composition comprising the synthesis of said radioactive agent according to the method of the invention.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 30, 2020
    Assignee: LABORATOIRES CYCLOPHARMA
    Inventor: Gilles Viot
  • Patent number: 10682430
    Abstract: The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 16, 2020
    Assignee: BAYER AS
    Inventor: Thomas Ramdahl
  • Patent number: 10668162
    Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: June 2, 2020
    Assignee: LinXis B.V.
    Inventors: Hendrik Jan Houthoff, Augustinus A. M. S. Van Dongen, Robbert Jan Kok, Dennis Christian Johannes Waalboer, Sytze Jan Buwalda, Niels Jurriaan Sijbrandi
  • Patent number: 10670605
    Abstract: Disclosed herein are methods, compositions, probes, polypeptides, assays, and kits for identifying a cysteine containing protein as a binding target for a small molecule fragment. Also disclosed herein are methods, compositions, and probes for mapping a biologically active cysteine site on a protein and screening a small molecule fragment for interaction with a cysteine containing protein.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 2, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Keriann M. Backus, Bruno E. Correia, Megan M. Blewett, John R. Teijaro
  • Patent number: 10668175
    Abstract: The invention relates to Cathepsin-binding compounds bound to a carrier comprising a diagnostic moiety, for use in the diagnosis of inflammatory diseases, and/or for use in the diagnosis of neoplastic diseases, wherein the Cathepsin-binding compound binds to inflammatory cells of the tumour stroma. The invention also relates to Cathepsin B-targeting compounds and Cathepsin B-binding and liposome-binding compounds.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 2, 2020
    Assignee: J. Stefan Institute
    Inventors: Olga Vasiljeva, Georgy Mikhaylov, Boris Turk, Norbert Schaschke
  • Patent number: 10669358
    Abstract: Element tags based on novel metal-polymer conjugates are provided for elemental analysis of analytes, including ICP-MS. A polymer backbone is functionalized to irreversibly bind metals that are selected prior to use by the user. The polymer is further functionalized to attach a linker which allows for attachment to antibodies or other affinity reagents. The polymer format allows attachment of many copies of a given isotope, which linearly improves sensitivity. The metal-polymer conjugate tags enable multiplexed assay in two formats: bulk assay, where the average biomarker distribution in the sample is diagnostic, and single cell format to distinguish a rare (for example a diseased) cell in a complex sample (for example, blood).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 2, 2020
    Assignee: FLUIDIGM CANADA INC.
    Inventors: Mitchell A. Winnik, Mark Nitz, Vladimir Baranov, Xudong Lou
  • Patent number: 10653822
    Abstract: The disclosure provides drug delivery devices and methods of making and using the drug delivery devices. The devices include single and multi-layer polymer films made by a breath figure technique having therapeutic agents associated therewith. For example, the devices may be a dual layer polymer film wherein the first layer includes a therapeutic agent incorporated into it by spin coating the first agent with a polymer solution and the second agent is incorporated into the second layer by loading the agent into pores of the second layer after it is spin coated onto the first layer. In some cases one layer provides a burst release and the second layer provides a slow release drug delivery profile. The devices may take on the form of a surgical mesh with a slow release therapeutic drug.
    Type: Grant
    Filed: August 11, 2018
    Date of Patent: May 19, 2020
    Assignee: THE ADMINSTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Diane A. Blake, Vijay T. John, Ramesh Ayyala, Thiruselvam Ponnusamy
  • Patent number: 10647986
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 12, 2020
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jocelyn Laporte, Belinda Cowling, Hichem Tasfaout
  • Patent number: 10639492
    Abstract: A head covering garment is configured to administer electromagnetic therapy to treat a cancerous tumor within a brain. The head covering garment includes a crown, which contains within its walls at least two magnetic coils (also referred to herein as solenoid coils). Each solenoid coil is energized, when in therapeutic operation, with a distinct time-domain signal. The time-domain signal consists of a series of summed sinusoidal waves from a power supply. The coils are oriented within the wall of the solenoid assembly such that for any two coils a first magnetic coil and a second magnetic coil are oriented relative to each other so as to be nonparallel. The purpose of having two distinct coils is to focus resultant magnetic fields such that at a tumor site within the brain encloses to form a local maximum formed by superposition within the cancerous tumor.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: May 5, 2020
    Inventor: Darin Cook
  • Patent number: 10640831
    Abstract: Disclosed is a diagnostic panel of methylated genomic loci encoding microRNA (mgmiR) markers that demonstrated 90% sensitivity and 100% specificity in the detection of head and neck squamous cell carcinoma (HNSCC). These results represent the first use of quantitative MS-PCR for the detection of mgmiRs. In addition this panel demonstrates the ability to detect hypermethylation in the adjacent mucosa of cancer patients, suggesting its utility in early detection. This panel is also capable of detecting cancer by using saliva, blood and FNA tissue samples.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: May 5, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Shi-long Lu, John Song
  • Patent number: 10624982
    Abstract: Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (B2O3) intermixed into a carrier which is an ointment, cream, or surgical glue.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: April 21, 2020
    Assignee: The Curators of the University of Missouri
    Inventors: Steven B. Jung, Delbert E. Day
  • Patent number: 10624846
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 21, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10610484
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 7, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10614547
    Abstract: An adaptive template image for registering a PET or a SPECT image includes a template image model including variability of values for each voxel in a template image according to one or more control parameters.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: April 7, 2020
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Roger Lundqvist, Nils Lennart Thurfjell, Johan Lilja
  • Patent number: 10607721
    Abstract: The present disclosure provides for rapid identification of mechanism of action (MOA) for drugs and toxins, and does so in a rapid (30 days or less) fashion. The methods use a combination of high throughput bioinformatics and pathway analysis that examine a wide variety of biological parametics.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 31, 2020
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Richard Caprioli, John Wikswo, John McLean, Eric Skaar, Jeremy L. Norris, Dana Borden Lacy, Stacy Sherrod, James Pino, Danielle Gutierrez, Nicole D. Muszynski, Melissa Farrow
  • Patent number: 10604516
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 31, 2020
    Assignee: National Institutes for Quantum and Radiological Science and Technology
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10596111
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: March 24, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10596112
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: March 24, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10588916
    Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: March 17, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
  • Patent number: 10568870
    Abstract: The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 25, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Israel Charo, Heiyoun Jung, Thomas J. Schall, Penglie Zhang
  • Patent number: 10562835
    Abstract: Disclosed herein are embodiments of a method for producing thorium-226. The method comprises separating thorium-226 from uranium-230 to produce a solution of thorium-226 in a solvent, such as a chelating buffer, suitable for direct labeling by a chelate. The thorium-226 may be separated from the uranium-230 using extraction chromatography. The extraction may be repeated multiple times as additional thorium-226 is produced by uranium-230 decay.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 18, 2020
    Assignee: Triad National Security, LLC
    Inventors: Michael E. Fassbender, Tara E. Mastren
  • Patent number: 10562952
    Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Crystal L. Mackall, Yongzhi Karen Cui
  • Patent number: 10539976
    Abstract: A docking device operates in an active mode or a passive mode. The docking device includes a path control module, a processing module and a switch. The processing module is connected to the switch, and the switch is connected between the path control module and the processing module. The path control module is configured to receive a signal from a host device. When the path control module does not receive the signal from the host device, the docking device operates in the active mode, and the processing module is connected to a plurality of function modules through the switch. When the path control module receives the signal from the host device, the docking device operates in the passive mode, and the path control module is connected to the function modules through the switch.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: January 21, 2020
    Assignee: GOOD WAY TECHNOLOGY CO., LTD.
    Inventors: Ying-Hao Lin, Wen-Hsien Chan, Chin-Chang Chang, Chih-Ming Tsao
  • Patent number: 10507247
    Abstract: An optical probe is presented comprising at least one fluorophore connected to at least one quencher by an enzyme cleavable peptide sequence; the or each fluorophore being substantially fluorescently quenched by the at least one quencher when connected to the enzyme cleavable peptide sequence; the or each fluorophore is separated from the at least one quencher when the enzyme cleavable peptide sequence of the at least one probe element is cleaved; and the enzyme cleavable peptide sequence is selectively cleavable by one or more matrix metalloproteinase (MMP). Methods of use of the optical probe are also presented.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 17, 2019
    Assignee: The University of the University of Edinburgh
    Inventors: Mark Bradley, Sunay Vijaykumar Chankeshwara, Alicia Megia-Fernandez
  • Patent number: 10495553
    Abstract: The present disclosure relates to an aqueous sealing fluid for sealing a stained biological specimen present on a microscope slide for microscopic analysis. The sealing fluid protects the biological specimen from drying artifacts, protects stains performed on biological specimen from fading, and protects stains performed on biological specimens from being dissolved by organic mounting media. Methods of using the aqueous sealing fluid are also disclosed.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: December 3, 2019
    Assignees: Diagnostic BioSystems
    Inventor: Marc Key
  • Patent number: 10493107
    Abstract: The present invention relates to an implantable therapeutic delivery system, methods of treatment utilizing the implantable therapeutic delivery system, and methods of fabricating the implantable delivery system. A first aspect of the present invention is directed to an implantable therapeutic delivery system. This therapeutic delivery system comprises a substrate, an inner polymeric coating that surrounds the substrate, and an outer hydrogel coating that surrounds said inner polymeric coating. One or more therapeutic agents are positioned in the outer hydrogel coating.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: December 3, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Minglin Ma, James A. Flanders, Duo An
  • Patent number: 10485846
    Abstract: Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 26, 2019
    Assignee: Tufts University
    Inventors: Ira M. Herman, Tatiana Demidova-Rice
  • Patent number: 10488418
    Abstract: Provided is a method for quantifying sugar appearing in a biological fluid of a subject, the method include (a) obtaining a biological sample from a subject, who has ingested one or more sugars, over a period of 0 to 24 hours after the ingesting; and (b) measuring the amount of the one or more sugars in the biological sample with an organoborane compound coupled to a fluorophore. Also provided are assays and kits for performing the above methods.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: November 26, 2019
    Assignee: The Regents of the University of California
    Inventors: Bakthan Singaram, Angel Resendez, Dominic Luc Webb
  • Patent number: 10478432
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Patent number: 10449261
    Abstract: The present invention is directed towards the compositions of peptide constructs that bind to GRP78 and the methods of use thereof.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: October 22, 2019
    Assignee: WASHINGTON UNIVERSITY
    Inventor: Dennis E. Hallahan
  • Patent number: 10442868
    Abstract: The specification provides compositions and methods of reducing a risk of a HBV infection in a subject and of treating a subject infected with HBV.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 15, 2019
    Assignee: Rhode Island Hospital, A Lifespan-Partner
    Inventors: Jack R. Wands, Jisu Li, Shuping Tong
  • Patent number: 10435465
    Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 8, 2019
    Assignee: NB HEALTH LABORATORY CO. LTD.
    Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
  • Patent number: 10434190
    Abstract: The invention provides methods for pre- and intra-operatively localizing penile sentinel lymph nodes by injection of fluorescent dyes into penile tumors.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: October 8, 2019
    Assignee: NOVADAQ TECHNOLOGIES ULC
    Inventors: Dragan Golijanin, Lukasz Brzozowski, Ronald Wood
  • Patent number: 10434191
    Abstract: The present invention relates to methods of visualising cells especially although not exclusively in vivo using a dye, such as a dendrimer-dye molecule or polybranched-dye molecule which is internalised by the cells and thus permits subsequent visualisation by confocal fluorescence endomicroscopy or other optical detectors. There is also provided internally quenched probes for use in visualising cells especially although not exclusively in vivo by confocal fluorescence endomicroscopy and the use of internally quenched probes in combination with confocal fluorescence endomicroscopy, for visualising cells by virtue of internalisation and dequenching of a probe by the cells. In a particular embodiment the cells are activated neutrophils, such as within the lung of a subject.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: October 8, 2019
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Tashfeen Walton, Mark Bradley, Kev Dhaliwal, Nikolaos Avlonitis, Chris Haslett, Neil McDonald, Manuelle Debunne
  • Patent number: 10426842
    Abstract: Provided are nanoparticle conjugates comprising a drug encapsulated in a gelatin nanoparticle the surface of which is functionalized with an antibody to which a siRNA is linked. Methods with the nanoconjugates for treating diseases are provided as well.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 1, 2019
    Assignee: The Curators of the University of Missouri
    Inventors: Raghuraman Kannan, Srikar Raman, Anandhi Upendran, Dhananjay Suresh
  • Patent number: 10420851
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 24, 2019
    Assignee: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik Dave, Shubh Sharma
  • Patent number: 10418159
    Abstract: The present invention relates to a magnetic nanoparticle comprising: a) a core containing a ferromagnetic material; b) an outer coating containing a mixture of a lipophilic compound and a hydrophilic compound. The outer coating of the above particle makes the nanoparticle stable in water and, simultaneously, capable of adsorbing/emulsifying large amounts of hydrophobic/lipophilic compounds. The present invention further relates to a process for the preparation of the above-mentioned particles as well as their use in the removal of hydrocarbons from solid or liquid environments and metal ions from contaminated water (wastewater).
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: September 17, 2019
    Assignee: POLITECNICO DI MILANO
    Inventors: Davide Moscatelli, Maurizio Masi, Ruggiero Maria Pesce
  • Patent number: 10400016
    Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 3, 2019
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
  • Patent number: 10385108
    Abstract: Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (?-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the ?-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 20, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Michael A. Perricone, John Lyle Dzuris, Timothy E. Weeden, James E. Stefano, Clark Q. Pan, Andrea E. Edling
  • Patent number: 10377795
    Abstract: A binding agent is capable of binding to rare earth materials such as rare earths and inorganic compounds thereof. A rare earth material-binding agent includes a peptide capable of binding to a rare earth material including a rare earth and a rare earth inorganic compound.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 13, 2019
    Assignee: KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO
    Inventors: Takaaki Hatanaka, Nobuhiro Ishida
  • Patent number: 10376858
    Abstract: The present invention relates to a method of producing an oligomer array. The invention comprises the steps of: providing a substrate with a multitude of recesses; introducing a first particle with a first molecule into a recess; releasing the first molecule from the first particle; binding the first molecule to a second molecule to form an oligomer while immobilizing the second molecule in the recess; optionally repeating the steps, wherein at least one of the first particles and/or the first molecules comprises a detectable marker.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: August 13, 2019
    Assignee: KARLSRUHER INSTITUT FUER TECHNOLOGIE
    Inventors: Alexander Nesterov-Mueller, Valentina Bykovskaya, Clemens Matthias von Bojnicic-Kninski, Felix Friedrich Loeffler, Roman Popov, Barbara Ridder, Frank Breitling, Daniela Silke Althuon
  • Patent number: 10377756
    Abstract: The present invention is directed towards a new method of synthesis of 18F-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[F]fluoride, as well as 18F-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: August 13, 2019
    Assignee: MERCK & CIE
    Inventors: Simon Mensah Ametamey, Rudolf Moser, Tobias Ludwig Ross, Phoebe Lam, Viola Groehn
  • Patent number: 10357575
    Abstract: A stabilized nanobubble can include a membrane that defines at least one internal void, which includes at least one gas. The membrane can include at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: July 23, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Agata Exner, Tianyi Krupka, Luis Solorio
  • Patent number: 10351551
    Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
  • Patent number: 10342849
    Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical composition which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion that can include sodium citrate, succinic acid, xylitol, glutamic acid, and ethylenediaminetetraacetic acid (EDTA), among others. Additionally disclosed pharmaceutical composition may include active pharmaceutical ingredients (API) such as antibiotics. Subsequently, the antibiotics agent may be ciprofloxacin, amikacin, tobramycin, colistin methate, or polymixin, among others. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 9, 2019
    Assignee: Professional Compounding Centers of America (PCCA)
    Inventor: Andrew B. Glasnapp
  • Patent number: 10335504
    Abstract: Probes which target diffuse and fibrillar forms of amyloid beta (A?) are described. These probes demonstrate high initial brain penetration and facile clearance from non-targeted regions. The agents can be used to image amyloid quantitatively for monitoring efficacy of A?-modifying therapeutics and assist in premortem diagnosis of Alzheimer's disease (AD). Disclosed probes can bind A? aggregates of preformed A?1-42 fibrils in vitro and can be used to image fibrillar and diffuse plaques ex vivo in brain sections. Disclosed probes can be used to determine A? burden in early stages of AD. These probes can be used for multimodality imaging of A?. F-AI-187 (1 ?M) can detect A? plaques in brain sections of APP/PS1 mice. F-AI-187 (10 ?M) can detect A? plaques in the frontal lobe in a brain section of a patient with confirmed AD. Some probes can be used for fluorescence imaging of plaque.
    Type: Grant
    Filed: April 2, 2016
    Date of Patent: July 2, 2019
    Assignee: Washington University
    Inventors: G. S. M. Sundaram, Jothilingam Sivapackiam, Vijay Sharma